Research ExplorerPublicationsDecrease in CD4+ T-cell counts in patients with multiple mye...

Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib.

Standard

Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib. / Heider, Ulrike; Rademacher, Jessica; Kaiser, Martin; Kleeberg, Lorenz; von Metzler, Ivana; Sezer, Orhan.

In: CL LYMPH MYELOM LEUK, Vol. 10, No. 2, 2, 2010, p. 134-137.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Heider, U, Rademacher, J, Kaiser, M, Kleeberg, L, von Metzler, I & Sezer, O 2010, 'Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib.', CL LYMPH MYELOM LEUK, vol. 10, no. 2, 2, pp. 134-137. <http://www.ncbi.nlm.nih.gov/pubmed/20371447?dopt=Citation>

APA

Heider, U., Rademacher, J., Kaiser, M., Kleeberg, L., von Metzler, I., & Sezer, O. (2010). Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib. CL LYMPH MYELOM LEUK, 10(2), 134-137. [2]. http://www.ncbi.nlm.nih.gov/pubmed/20371447?dopt=Citation

Vancouver

Heider U, Rademacher J, Kaiser M, Kleeberg L, von Metzler I, Sezer O. Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib. CL LYMPH MYELOM LEUK. 2010;10(2):134-137. 2.

Bibtex

@article{3cf72e8f5aed4b78bbb3727569a24fd8,
title = "Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib.",
abstract = "Bortezomib is highly effective in multiple myeloma and is widely used in this disease. Recently, an increased incidence of varicella zoster virus (VZV) reactivation was reported in patients with myeloma undergoing bortezomib treatment.",
keywords = "Humans, Male, CD4 Lymphocyte Count, T-Lymphocytes immunology, Multiple Myeloma drug therapy, Acyclovir immunology, Boronic Acids, CD4-Positive T-Lymphocytes immunology, Herpes Zoster drug therapy, Herpesvirus 3, Human drug effects, Pyrazines, Humans, Male, CD4 Lymphocyte Count, T-Lymphocytes immunology, Multiple Myeloma drug therapy, Acyclovir immunology, Boronic Acids, CD4-Positive T-Lymphocytes immunology, Herpes Zoster drug therapy, Herpesvirus 3, Human drug effects, Pyrazines",
author = "Ulrike Heider and Jessica Rademacher and Martin Kaiser and Lorenz Kleeberg and {von Metzler}, Ivana and Orhan Sezer",
year = "2010",
language = "Deutsch",
volume = "10",
pages = "134--137",
journal = "CL LYMPH MYELOM LEUK",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "2",

}

RIS

TY - JOUR

T1 - Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib.

AU - Heider, Ulrike

AU - Rademacher, Jessica

AU - Kaiser, Martin

AU - Kleeberg, Lorenz

AU - von Metzler, Ivana

AU - Sezer, Orhan

PY - 2010

Y1 - 2010

N2 - Bortezomib is highly effective in multiple myeloma and is widely used in this disease. Recently, an increased incidence of varicella zoster virus (VZV) reactivation was reported in patients with myeloma undergoing bortezomib treatment.

AB - Bortezomib is highly effective in multiple myeloma and is widely used in this disease. Recently, an increased incidence of varicella zoster virus (VZV) reactivation was reported in patients with myeloma undergoing bortezomib treatment.

KW - Humans

KW - Male

KW - CD4 Lymphocyte Count

KW - T-Lymphocytes immunology

KW - Multiple Myeloma drug therapy

KW - Acyclovir immunology

KW - Boronic Acids

KW - CD4-Positive T-Lymphocytes immunology

KW - Herpes Zoster drug therapy

KW - Herpesvirus 3, Human drug effects

KW - Pyrazines

KW - Humans

KW - Male

KW - CD4 Lymphocyte Count

KW - T-Lymphocytes immunology

KW - Multiple Myeloma drug therapy

KW - Acyclovir immunology

KW - Boronic Acids

KW - CD4-Positive T-Lymphocytes immunology

KW - Herpes Zoster drug therapy

KW - Herpesvirus 3, Human drug effects

KW - Pyrazines

M3 - SCORING: Zeitschriftenaufsatz

VL - 10

SP - 134

EP - 137

JO - CL LYMPH MYELOM LEUK

JF - CL LYMPH MYELOM LEUK

SN - 2152-2650

IS - 2

M1 - 2

ER -